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Abstract
Persistent opening of the mitochondrial permeability transition pore (PTP), an inner membrane 
channel, leads to mitochondrial dysfunction and renders the PTP a therapeutic target for a host of 
life-threatening diseases. Herein, we report our effort toward identifying small-molecule inhibitors 
against this target through structure-activity-relationship optimization studies, which led to the 
identification of several potent analogs around the N-phenylbenzamide compound series identified 
by high-throughput screening. In particular, compound 4, (3-(benzyloxy)-5-chloro-N-(4-
(piperidin-1-ylmethyl)phenyl)benzamide), displayed noteworthy inhibitory activity in the 
mitochondrial swelling assay (EC50 of 280 nM), poor to very good physicochemical as well as in 
vitro pharmacokinetic properties, and conferred very high calcium retention capacity to 
mitochondria. From the data, we believe compound 4 in this series represents a promising lead for 
the development of PTP inhibitors of pharmacological relevance.
Calcium deregulation adjourned
Persistent opening of the mitochondrial permeability transition pore (PTP), which is a Ca2+-
release megachannel, causes cell death. Here we describe the discovery of potent N-
phenylbenzamide compounds as PTP inhibitors that confer very high calcium retention capacity to 
the mitochondria that also possess good-to-very good pharmacological profiles.
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It has been appreciated for some time that the mitochondrial permeability transition pore 
(PTP), a channel of the inner mitochondrial membrane (IMM), can inappropriately open in a 
variety of human pathologies.[1] Persistent opening of pore causes depolarization, release of 
matrix Ca2+, cessation of oxidative phosphorylation and may result in mitochondrial 
swelling and rupture of outer mitochondrial membrane (OMM) culminating in cell death.[2] 
The molecular nature of the PTP has been clarified only recently. Traditional models of PTP 
involving complexes of OMM and IMM proteins have been discounted on the basis of 
genetic studies showing the PTP can still form in the absence of each of these proteins.[3–4] 
Other recent studies have suggested that dimers of the FOF1 ATP synthase (F-ATP synthase) 
are able to form channels with properties expected for the PTP.[5] The precise nature of the 
molecular transition of this complex from a Mg2+-dependent ATP synthetic device into a 
Ca2+-dependent pore has yet to be determined. While progress has been made on the 
molecular identity of PTP, our ability to treat diseases in which inappropriate activation of 
the PTP plays a role has been limited to the use of cyclosporin A (CsA) and its analogs, 
Debio 025 and NIM811, which act on the pore through their matrix receptor and PTP 
modulator cyclophilin D (CyPD).[6]
In vivo treatment has proven effective in models of collagen VI muscular dystrophy[7–11] 
and provided encouraging results in a pilot trial on patients affected by Ullrich Congenital 
Muscular Dystrophy and Bethlem Myopathy.[12] The limit of cyclophilin inhibitors is that 
their target, CyPD, modulates the pore indirectly, as shown by the fact that the PTP can still 
open when CyPD has been genetically ablated.[13–16] Therefore, we[17] as well as others[18] 
have carried out programs aimed at identifying novel PTP inhibitors through the unbiased 
screening of compound libraries. Here, we report a novel series of potent small-molecule 
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inhibitors of the PTP that can be used as investigative tools, and possibly, developed into 
therapeutics for PTP-based diseases.
A high-throughput screen of the Molecular Libraries Small Molecule Repository (MLMSR) 
collection of 363,827 compounds revealed benzamide compounds 1 and 2 (Figure 1), among 
several other hits (data not presented), that were chosen as starting points for structure-
activity-relationship (SAR) studies based on their biological activity and physicochemical 
properties.[19] The two keys assays that were used to identify the hits were: (i) Ca2+-induced 
mitochondrial swelling, a light-scattering-based assay that depends on PTP opening that 
allowed us to identify the inhinitors and assess their concentration-response, and (ii) 
Rhodamine (Rh) 123-uptake, a counterscreen assay which allowed us to identify compounds 
that prevent Ca2+ uptake by interfering with development or maintenance of the IMM 
potential, thereby preventing mitochondrial swelling by preventing Ca2+ entry rather than by 
inhibiting the PTP. Indeed, Ca2+ uptake through the selective mitochondrial Ca2+ uniporter 
in respiring mitochondria is driven by the Ca2+ electrochemical gradient, which does not 
form if the test compound inhibits respiration and/or has uncoupling properties.
During the hit validation and SAR optimization stages of the project, in addition to the 
mitochondrial swelling and Rh123-uptake assays, we used the Ca2+ retention capacity 
(CRC) assay, a sensitive method that allows one to define precisely the effect of inhibitors 
on the Ca2+-dependent propensity of the pore to open.[20–21] To the best of our knowledge, 
this is the first report of the inhibitory activity of N–phenylbenzamide compounds toward 
the PTP.
The benzamide analogs were assembled in a two-step process (Scheme 1). The 3-
hydroxybenzoic acid derivatives 5 were treated with either substituted or unsubstituted 
benzyl bromide along with potassium carbonate in DMF for 24 h to give the corresponding 
benzyl 3-(benzyloxy)benzoate derivatives. These benzoate esters were then saponified with 
10 M potassium hydroxide in MeOH under reflux conditions to yield the corresponding 
carboxylic acids 6 in 50–80% yield. Subsequent PyBOP-mediated amide coupling reactions 
with various substituted anilines 7 in the presence of Hunig’s base and DMF under 
microwave conditions afforded the corresponding analogs 8 of the benzamide series.
A SAR campaign was carried out around the hit molecules, 1 and 2, that led to couple of 
very potent analogs, 3 and 4, out of 82 analogs that were screened.[22] Results for a 
representative SAR study that was mainly focused on investigating the 6-membered 
heterocyclic pendant attached to the eastern aryl ring (12–15) as well as on studying the 
effect of halogen substitution around the western half of the structure (9–11 and 16–20) have 
been summarized in Table 1. These studies revealed that replacement of the pendant 
piperidine with piperizines (14 and 15) in the eastern region was well-tolerated and afforded 
compounds with similar potency at preventing mitochondrial swelling that increased the 
CRC of mitochondria as well. All other changes failed afford compounds with any 
significant improvement in activity compared to 3 and 4 (Figure 1 and Table 2). As noted in 
Table 1, most of the analogs showed activity in the Rh123 uptake assay, suggestive of 
interference with the IMM, an untoward side effect. The strategy to replace chloro with a 
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fluoro substituent in the western aryl ring resulted in analogs 9 and 10 with a much-
improved profile in the counterscreen and CRC assays.
Clearly compounds 3 and 4 (Figure 1 and Table 2) demonstrated the best activity in the 
swelling and CRC assays. Of the two compounds, 4 showed slightly superior activity and, 
hence, was chosen for extensive biological characterization using a variety of established in 
vitro assays. First, we examined PTP-dependent swelling in isolated mouse liver 
mitochondria following uptake of 50 μM Ca2+. In a full concentration-response ranging 
from 12.2 nM to 1.56 μM, inhibition of swelling was demonstrated with an EC50 of 0.398 
± 0.025 μM (Figure 2A) which is in the same order of magnitude as for standard PTP 
inhibitors CsA and GNX-865,[18] a cinnamic anilide identified in a high-throughput screen 
similar to the one employed here (Table 1). We next tested the CRC, which allows 
quantification of the amount of Ca2+ necessary to open the pore. At 12.5 μM a compound-
to-solvent CRC ratio of 19 was generated, the highest reported in the literature to date 
(Figure 2B). We also observed that the maximum CRC ratios of isolated mouse liver 
mitochondria treated with 4 are about 4 times higher than ones treated with CsA, which 
implied that the compounds might be acting on different biological targets. To test this 
hypothesis, we investigated the threshold Ca2+ load required for the PTP to open in response 
to 4 in CyPD-null mouse liver mitochondria, which lack the mitochondrial CsA binding site. 
We observed a 7-fold increase in CRC in these mitochondria (which are already partially 
desensitized due to the absence of CyPD), suggesting that benzamides have a different 
molecular target. Maximal PTP inhibition by 4, as assessed by both mitochondrial swelling 
and CRC assays, occurred at concentrations higher than those observed with 
diarylisoxazole-3-carboxamides, the other class of inhibitors that was identified in the high-
throughput screen.[17]
We also tested whether 4 is protective against known inducers of the PTP that trigger pore 
opening by inducing oxidative stress. Isolated mouse liver mitochondria were loaded with 10 
μM Ca2+ (which is not able to induce PTP opening per se, Figure 2D traces a) and then 
challenged with reagents that modify distinct classes of redox-sensitive thiols (–SH) (traces 
b) which affect the PTP sensitivity to Ca2+ and trigger pore opening: (a) matrix –SH groups 
that react with diamide and PhAsO,[23] (b) inner membrane external thiols that react with 
copper (II) bis(1,10-phenanthroline) complex [Cu(OP)2], and (c) outer membrane N-
ethylmaeimide (NEM)-reactive thiols.[24–25] In all cases, the PTP transition from the closed 
to open conformation was delayed by 3.12 μM CsA (traces c) and prohibited by the same 
concentration of 4 (traces d), as assessed in mitochondrial swelling assays (Figure 2D). 
Therefore, these inhibitors are effective in preventing PTP opening regardless of the methods 
used to induce it.
In all the above-mentioned studies, murine mitochondria were used for identifying and 
optimizing PTP inhibitors. However, due to the existence of species-specific PTP 
regulation,[26–28] we deemed it essential to test whether an inhibitory effect could be also 
detected in human mitochondria. As demonstrated in Figure 2E, compound 4 induced a 
concentration-dependent increase in the CRC of permeabilized HeLa cells.
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It has been suggested that the PTP forms from a unique conformation of dimers (or higher 
oligomeric forms) of F-ATP synthase.[5] In light of these findings, we investigated whether 4 
also affects ATP synthesis, which would be potentially an undesirable side effect. 
Mitochondrial respiration was measured both in isolated mouse liver mitochondria and in 
intact HeLa cells in the presence or absence of 4. No significant differences were observed 
in respiratory control ratios, FCCP-stimulated, and oligomycin-sensitive respiration in either 
isolated mouse liver mitochondria (Figure 2C and data not shown) or HeLa cells (Figure 2F) 
at low concentrations of 4 (i.e., ≤ 10 μM). A decrease in the IMM potential (Figure 2A) and 
respiratory control ratio (Figure 2C) in isolated mouse liver mitochondria (reflecting a 
decreased ability to generate ATP) and of oxygen-consumption rate in HeLa cells was 
observed only at higher concentrations of 4. These findings confirm that compound 4 shows 
no effect on ATP synthesis and HeLa cell proliferation at low concentrations (5 μM and ≤ 10 
μM, respectively). However, at concentrations above 10 μM it may cause cellular toxicity, as 
confirmed in HeLa (Figure 2G) and Fa2N-4 cells (Table 2, last entry).
We next examined the physicochemical and in vitro pharmacokinetic properties for the 
analogs 3 and 4 (Figure 1 and Table 2). Analogs 3 and 4 displayed promising 
physicochemical parameters, possessing a desirable number of hydrogen bond donors and 
acceptors, reduced topological polar surface area, molecular weight less than 500 Da, and 
moderately favorable ligand efficiency. Although the cLogP values were generally high for 3 
and 4 (above 6), analogs 14 and 15 had much reduced cLogP values around 4.9. These key 
analogs were characterized further for in vitro pharmacology to create a baseline profile for 
future structure-property-relationship (SPR) optimization efforts. Overall, analogs 3 and 4 
demonstrated poor-to-very good in vitro pharmacokinetic features, having poor-to-good 
aqueous solubility (pH dependent) and good chemical stability in the presence of excess 
dithiotreitol (DTT), confirming that these inhibitors do not possess reactive functionality. 
Compounds 3 and 4 demonstrated moderate plasma stability and very high plasma protein 
binding. A parallel artificial membrane permeability assay (PAMPA) was used as an in vitro 
model for passive transport, and blood-brain barrier (BBB) permeability was used to predict 
CNS penetration. Compounds 3 and 4 demonstrated very good permeability in both of these 
assays. Metabolic liability was apparent for both 3 and 4 after 1 h exposure, especially in 
mouse liver microsomes in the presence of NADPH. The key analogs showed some degree 
of toxicity towards Fa2N-4 immortalized human hepatocytes, having LC50s of 30 and 32 μM 
with 75-fold and 114-fold selectivity compared to the EC50s for the mitochondrial swelling 
for 3 and 4, respectively. Activity of these key analogs in the Rh123 uptake and cytotoxicity 
assays suggests a possible trend, which will be monitored during future studies.
In summary, SAR optimization studies around the N-phenylbenzamide scaffold led to the 
discovery of potent inhibitors of the PTP conferring mitochondria with a very high CRC, 
which is a robust measure of inhibition of the PTP. Compound 4 confers a CRC ratio of 19 
(the highest reported for a PTP inhibitor to date) and showed promising inhibition of 
swelling, with an EC50 of 280 nM. We carried out biological characterization of the PTP 
through a series of in vitro assays and found that compound 4 was protective against both 
Ca2+− and oxidative-stress-triggered pore opening, and that it inhibits both the mouse and 
human PTP. Moreover, we found that the biological target for this compound series is not 
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CyPD, and that no inhibition of F-ATP synthase is observed at concentrations that fully 
inhibit the PTP. Higher concentration (>10 μM) of compound 4 showed interference with the 
IMM potential and cytotoxicity. Overall, this compound series, represented by compounds 3 
and 4, possesses a promising in vitro pharmacological profile, poor-to-good aqueous 
solubility (pH-dependent), and good permeability. Future studies will involve additional 
optimization in order to decrease compound toxicity and provide anaolgs suitable for in vivo 
testing for efficacy in relevant disease models.
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Figure 1. 
Compounds 3 and 4 derived from hits 1 and 2.
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Figure 2. 
Effect of 4 on the PTP and cell viability. (A) Full symbols: 4 prevents mitochondrial 
swelling induced with 50 μM Ca2+ in a concentration-dependent manner; open symbols: 
interference with Rh123 uptake upon treatment with compound 4; (B) Concentration-
response of 4-to-solvent CRC ratios of WT (squares) and CyPD KO (triangles) 
mitochondria; (C) respiratory control ratios (RCR) of 4 or solvent-treated mouse liver 
mitochondria; (D) Effect of 4 with known chemical inducers of the PTP. Mitochondria were 
supplemented with 10 μM Ca2+ only, traces a; 10 μM Ca2+ and with, as indicated, 7 μM 
PhAsO, 2 mM Diamide, 7 μM Cu(OP)2 or 2 mM N-ethylmaleimide traces (b)–(d); in traces 
c and d 3.125 μM CsA or 4, respectively, were also present; (A)–(D) assays were performed 
on isolated mouse liver mitochondria. (E) 4-to-solvent CRC ratios of permeabilized HeLa 
cells (0.8 million/condition). (F) Oxygen-consumption rates (OCR) of HeLa cells, 
treatments were made as indicated. (G) Interference with HeLa cell proliferation after 24-
hour treatment with indicated concentration of 4. Data are a representative (D, F) and an 
average ± SEM of ≥ 4 experiments.
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Scheme 1. 
General procedure for synthesis of benzamide analogs.
Roy et al. Page 10
ChemMedChem. Author manuscript; available in PMC 2017 February 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Roy et al. Page 11
Table 1
Structure-activity-relationship optimization of representative analogs
Data are an average of ≥ 3 experiments ± SEM
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